The size of the Diabetic Retinopathy Market in North America was worth USD 2.45 billion in 2020 and is projected to reach USD 3.28 billion by 2025, growing at a CAGR of 6.05% during the forecast period.
Diabetic retinopathy plays a significant role in diagnosing damages blood vessels in the retina of an eye, and this is considered as a primary factor for the market to grow. Increasing the incidence of diabetes is propelling the demand of the market. Also, the rise in the investments by both private and public organizations on expanding healthcare centers is boosting up the growth of the market. Besides, growing obesity problems due to the adoption of sedentary lifestyles and also changes in food habits is straight leveling up the demand of the market in North America.
However, the lack of skilled persons in monitoring the systems is quietly declining the growth of the market. The cost of installation and maintenance of the devices is very high, and this is impeding the growth of the North American diabetic retinopathy market. The challenging factor that comes in for the market developers is rising risk and adverse effects due to long term use of the medicines.
Increasing expenditure on healthcare is ascribed to bolster the demand of the market. Rising need to provide adequate health management services in every healthcare center is fuelling the growth of the market. Increasing specialty care hospitals with the latest equipment is to set up growth opportunities for the market. The growing elderly population is elevating the demand of the market.
Based on the region, the U.S is holding the highest shares of the market. North America is the leading region in the Global Diabetic Retinopathy Market.
Rising awareness over the treatment procedures in urban areas is making the market share to expand. Increasing disposable income is another attribute magnifying the demand of the market. Growing demand for effective treatment procedures is gearing up the growth of the market.
The growing number of surgical treatments is prompting the demand of the market. The rise in the emergence of laser treatment procedures, which is minimal and straightforward pain procedure is broadening the growth of the market. Increasing support from the government by launching reimbursement schemes in favor of the ordinary people is spurring the growth of the diabetic retinopathy market.
Growing revenue from the past decade is elevating the demand of the market in this country. The emergence of advanced technology and also the launch of various diagnostic procedures in concern towards patient health safety is impacting positively on the growth of the market. A rise in the scale of healthcare centers and pharmacies is solely to expand the growth rate of the diabetic retinopathy market.
Companies like Bayer AG, Pfizer Inc., Hoffmann-La Roche ltd., Regeneron Pharmaceutical Inc., Novartis AG, Valeant Pharmaceutical International Inc., Abbott Laboratories Inc., Alimera Science Inc., and Ampio Pharmaceuticals Inc. are playing a leading role in the North American Diabetic Retinopathy Market.
This research report has been segmented and sub-segmented into the following categories:
By Treatment Type:
By Indication:
By End-User:
By Country:
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type of Treatment
5.1.1 Anti-Vascular Endothelial Growth Factor (VEGF) drug
5.1.2 Intraocular Steroid Injection
5.1.3 Laser Surgery
5.1.4 Vitrectomy
5.2 By Indication
5.2.1 Non-Proliferative Diabetic Retinopathy (NPDR)
5.2.1.1 Mild
5.2.1.2 Moderate
5.2.1.3 Severe
5.2.2 Proliferative Diabetic Retinopathy (PDR)
5.3 By End Users
5.3.1 Hospitals
5.3.2 Ophthalmic Clinics
5.3.3 Ambulatory Surgical Centers
6. Geographical Analysis
6.1 Introduction
6.2 United States
6.3 Canada
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Bayer AG
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Pfizer Inc.
8.3 Hoffmann-La Roche ltd
8.4 Regeneron Pharmaceutical Inc.
8.5 Novartis AG
8.6 Valeant Pharmaceutical International Inc.
8.7 Abbott Laboratories Inc.
8.8 Alimera Science Inc.
8.9 Ampio Pharmaceuticals Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
